Inhibikase Therapeutics's total assets for Q4 2024 were $98.60M, an increase of 2152.75% from the previous quarter. IKT total liabilities were $3.73M for the fiscal quarter, a -23.92% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.